Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details) - Pulmokine, Inc. - License Agreement - In Process Research And Development Seralutinib - USD ($)		1 Months Ended
	Oct. 02, 2017	Oct. 31, 2017	Jun. 30, 2023	Dec. 31, 2020
Business Acquisition [Line Items]
Product license term (in years)	10 years
Upfront payment		$ 5,500,000
Milestones accrued			$ 0	$ 5,000,000
Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable	$ 58,000,000
Initial phase three payment	10,000,000
Commercial milestone payments, payable	45,000,000
Sales milestone payments, payable	$ 190,000,000